Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab

Diagnostic Pathology

Shinichi Konno²  Kazuo Watanabe⁴  Kazuhiro Tasaki¹  Osamu Hasegawa³  Hitoshi Yamada²  Takahiro Tajino²  Michiyuki Hakozaki² 

[1] Department of Pathology and Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan;Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima-shi, Fukushima 960-1295, Japan;Department of Radiology, Fukushima Medical University School of Medicine, Fukushima, Japan;Fukushima Pathology Laboratory, Fukushima, Japan

关键词: Benign fibrous histiocytoma;    ¹⁸F-FDG PET/CT;    MRI;    Plain radiograph;    Receptor activator of nuclear factor-κB ligand (RANKL);    Neoadjuvant chemotherapy;    Denosumab;    Giant cell tumor of bone;   

Others  :  801471
DOI  :  10.1186/1746-1596-9-111

 received in 2014-03-25, accepted in 2014-05-15,  发布年份 2014

【 摘 要 】

We describe a case of giant cell tumor of the proximal tibia with skip bone metastases of the ipsilateral femur in a 20-year-old man. After the neoadjuvant treatment with denosumab, plain radiographs and computed tomography showed marked osteosclerosis and sclerotic rim formation, and ¹⁸F-FDG PET/CT showed a decreased standardized uptake value, whereas magnetic resonance imaging showed diffuse enhancement of the tumor, nearly the same findings as those at pretreatment. Pathological findings of the surgical specimen after the denosumab treatment showed benign fibrous histiocytoma-like features with complete disappearance of both mononuclear stromal cells and multinuclear osteoclast-like giant cells.

【 授权许可】

   
2014 Hakozaki et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Uni KK, Inwards CY: Giant cell tumor (osteteoclastoma). In Dahlin’s bone tumors. 6th edition. Edited by Uni KK, Inwards CY. Philadelphia: Lippincott Williams and Wilkins; 2010:225-242.
• [2]Athanasou NA, Bansal M, Forsyth R, Reid RP, Sapi Z: Giant cell tumour of bone. In WHO classification of tumours of soft tissue and bone. 4th edition. Edited by Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. Lyon: International Agency for Research on Cancer; 2013:321-324.
• [3]Hammas N, Laila C, Youssef ALM, Hind EF, Harmouch T, Siham T, Afaf A: Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience. Diagn Pathol 2012, 7:130. BioMed Central Full Text
• [4]Xu SF, Adams B, Yu XC, Xu M: Denosumab and giant cell tumour of bone—a review and future management considerations. Curr Oncol 2013, 20:e442-e447.
• [5]Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr: Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics 2013, 33:197-211.
• [6]Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S: Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.
• [7]Derbel O, Zrounba P, Chassagne-Clément C, Decouvelaere AV, Orlandini F, Duplomb S, Blay JY, de la Fouchardiere C: An unusual giant cell tumor of the thyroid: case report and review of the literature. J Clin Endocrinol Metab 2013, 98:1-6.
• [8]Karras NA, Polgreen LE, Ogilvie C, Manivel JC, Skubitz KM, Lipsitz E: Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol 2013, 31:e200-e202.
• [9]Agarwal A, Larsen BT, Buadu LD, Dunn J, Crawford R, Daniel J, Bishop MC: Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection. Case Rep Oncol Med 2013, 2013:496351.
• [10]NCI. CTCAEhttp://evs.nci.nih.gov/ftp1/CTCAE/About.html webcite
• [11]Miller IJ, Blank A, Yin SM, Mcnickle A, Gray R, Gitelis S: A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases. Diagn Pathol 2010, 5:62. BioMed Central Full Text
• [12]Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I: Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012, 18:4415-4424.
• [13]Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP: Gene expression in giant-cell tumors. J Lab Clin Med 2004, 144:193-200.
• [14]Josse R, Khan A, Ngui D, Shapiro M: Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Curr Med Res Opin 2013, 29:205-216.
• [15]Suzuki K: Current therapeutic strategy for multiple myeloma. Jpn J Clin Oncol 2013, 43:116-124.
• [16]Kurata T, Nakagawa K: Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer. Jpn J Clin Oncol 2012, 42:663-669.
• [17]Wirbel R, Blümler F, Lommel D, Syré G, Krenn V: Multicentric giant cell tumor of bone: synchronous and metachronous presentation. Case Rep Orthop 2013, 2013:756723.